Himani Tripathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Himani Tripathi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Tarun Kumar Bhatt
4 shared publications- Tarun Kumar Bhatt
Department of Biotechnology, School of Life Sciences Central University of Rajasthan, Bandarsindri, Kishangarh Ajmer Rajasthan India
4 shared publications - Anand Srivastava
National Institute of Animal Biotechnology (NIAB), Hyderabad, Telangana, India
1 shared publication Araveti Prasanna Babu
National Institute of Animal Biotechnology, Hyderabad, Telangana 500032, India
1 shared publication- Bader Saud Alotaibi
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Al- Quwayiyah, Shaqra University, Riyadh, Saudi Arabia
1 shared publication - Diwakar Kumar
Department of Microbiology Assam University Silchar Assam India
1 shared publication
Latest Publications
- 15 April 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 216, 108502
Designing a next-generation multi-stage vaccine for malaria prevention
- 15 April 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 216, 108502
Designing a next-generation multi-stage vaccine for malaria prevention
- Open Access
- 27 January 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
Development of a highly specific PrM-based diagnostic marker for dengue virus detection: minimizing cross-reactivity with other flaviviruses and SARS-CoV-2
- 27 January 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
Open AccessDevelopment of a highly specific PrM-based diagnostic marker for dengue virus detection: minimizing cross-reactivity with other flaviviruses and SARS-CoV-2
- 23 January 2026
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 115 (1) , 117281
Discovery of parasite proteins in the urine of vivax malaria patients through mass spectrometry
- 23 January 2026
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 115 (1) , 117281
Discovery of parasite proteins in the urine of vivax malaria patients through mass spectrometry
- 21 June 2024
- Published by Elsevier
- p. 215-236
Protozoan diseases having less global burden
- 21 June 2024
- Published by Elsevier
- p. 237-247
Summary of advancement in protozoan disease diagnosis and treatment
- 21 June 2024
- Published by Elsevier
- p. 237-247
Summary of advancement in protozoan disease diagnosis and treatment
- 21 June 2024
- Published by Elsevier
- p. 1-10
Brief introduction to infectious diseases
- Open Access
- 14 April 2023
- Published by Springer Nature in Parasites & Vectors
- Vol. 16 (1) , 1-26
Malaria therapeutics: are we close enough?
Malaria is a vector-borne parasitic disease caused by the apicomplexan protozoan parasite Plasmodium. Malaria is a significant health problem and the leading cause of socioeconomic losses in developing countries. WHO approved several antimalarials in the last 2 decades, but the growing resistance against the available drugs has worsened the scenario. Drug resistance and diversity among Plasmodium strains hinder the path of eradicating malaria leading to the use of new technologies and strategies to develop effective vaccines and drugs. A timely and accurate diagnosis is crucial for any disease, including malaria. The available diagnostic methods for malaria include microscopy, RDT, PCR, and non-invasive diagnosis. Recently, there have been several developments in detecting malaria, with improvements leading to achieving an accurate, quick, cost-effective, and non-invasive diagnostic tool for malaria. Several vaccine candidates with new methods and antigens are under investigation and moving forward to be considered for clinical trials. This article concisely reviews basic malaria biology, the parasite's life cycle, approved drugs, vaccine candidates, and available diagnostic approaches. It emphasizes new avenues of therapeutics for malaria. Graphical Abstract
- 14 April 2023
- Published by Springer Nature in Parasites & Vectors
- Vol. 16 (1) , 1-26
Open AccessMalaria therapeutics: are we close enough?
Malaria is a vector-borne parasitic disease caused by the apicomplexan protozoan parasite Plasmodium. Malaria is a significant health problem and the leading cause of socioeconomic losses in developing countries. WHO approved several antimalarials in the last 2 decades, but the growing resistance against the available drugs has worsened the scenario. Drug resistance and diversity among Plasmodium strains hinder the path of eradicating malaria leading to the use of new technologies and strategies to develop effective vaccines and drugs. A timely and accurate diagnosis is crucial for any disease, including malaria. The available diagnostic methods for malaria include microscopy, RDT, PCR, and non-invasive diagnosis. Recently, there have been several developments in detecting malaria, with improvements leading to achieving an accurate, quick, cost-effective, and non-invasive diagnostic tool for malaria. Several vaccine candidates with new methods and antigens are under investigation and moving forward to be considered for clinical trials. This article concisely reviews basic malaria biology, the parasite's life cycle, approved drugs, vaccine candidates, and available diagnostic approaches. It emphasizes new avenues of therapeutics for malaria. Graphical Abstract